SSY GROUP (02005) announced that the Group has obtained a drug production registration approval from China's National Medical Products Administration (NMPA) for Propafenone Hydrochloride Injection (20ml:70mg). Classified as a chemical drug category 3, the product is considered to have passed the consistency evaluation, making SSY the third domestic company to receive approval for this formulation. Propafenone Hydrochloride Injection is primarily indicated for the treatment of supraventricular tachycardia requiring intervention, such as atrioventricular junctional tachycardia, WPW syndrome with supraventricular tachycardia or paroxysmal atrial fibrillation, as well as ventricular tachycardia that requires treatment or is life-threatening.